Targets › MUCIN16
1 program from 1 company in 5 trials: 3 Phase 2, 2 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: the race on MUCIN16, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Ubamatamab Anti-MUC16 monoclonal antibody | MUCIN16 | Phase 2 | Ovarian Cancer; Non Small Cell Lung Cancer; Recurrent Ovarian Cancer; SMARCB1-Deficient Malignancies | May 2027 |
Ovarian Cancer (2) Non Small Cell Lung Cancer (1) Recurrent Ovarian Cancer (1) SMARCB1-Deficient Malignancies (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.